Alzheimer’s & Dementia

Filter Your Results

 

News

 

Innovative Drug Combination Addresses Neuroinflammatory Response and Amyloid-Beta Accumulation Associated with Alzheimer's Disease

Wednesday, January 31, 2018—AZTherapies, Inc., an advanced clinical stage pharmaceutical company developing breakthrough treatments for neurologic diseases associated with neuroinflammation and neurodege…

The National Institutes of Health Launches "Accelerating Medicines Partnership Parkinson's Disease" to Advance Treatment Research

Tuesday, January 30, 2018—As part of their Accelerating Medicines Partnership (AMP) initiative, which aims to foster collaboration among government, biopharmaceutical, life science, and non-profit orga…

The Generational Technology Gap May Be Closing—Even in Patients with Dementia

Tuesday, January 16, 2018—Senior Helpers, a provider of in-home services for seniors who wish to remain in their homes despite age-related illnesses and mobility challenges including dementia, Alzheime…

FDA Filing for Cannabidiol, Data on Diet and Exercise and Brain Aging and Memory, Boston Scientific Indication for DBS

January 2018—FDA Accepts NDA Filing of First Cannabis Plant-Derived Medicine On December 28, 2017, GW Pharmaceuticals announced that the US Food and Drug Administration (FDA) had accept…

The Prevalence of Migraine and Other Neurological Conditions Among Retired National Football League Players: A Pilot Study

Randolph W. Evans, MD

November/December 2017—Findings suggest that retired NFL players may be at increased risk for migraine, depression, anxiety, chronic pain, bedwetting, essential tremor, and Parkinson’s disease.

Forward Thinking: Advances in Neurology

November/December 2017—A review of notable neurological developments in 2017 and a preview of the year ahead.

The Cognitive and Behavioral Consequences of Hearing Loss, Part 2: Evaluation and Treatment

Ronald Devere, MD

November/December 2017—Although unrecognized hearing loss can affect quality of life and play a role in cognitive impairment, it may be reversible and/or treatable.

FDA Fast-Tracks Alzheon’s Anti-Amyloid Alzheimer’s Agent

Tuesday, October 24, 2017—The FDA has granted Fast Track designation to Alzheon, Inc.’s investigational anti-amyloid drug ALZ-801 for the treatment of Alzheimer’s disease (AD). Using a prec…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC